Genocea Biosciences Stock Forecast, Price & News NASDAQ:GNCA

You’ll receive continuously updated Zacks Rank and Style Scores, Earnings Estimate Revisions, Broker Recommendation Changes, Earnings Surprises and more. Note that you should also add your mutual fund and ETF positions to monitor changes in their Zacks Rank as well. Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. The values of total fails-to-deliver shares represent the aggregate net balance of shares that failed to be delivered as of a particular settlement date. Fails to deliver on a given day are a cumulative number of all fails outstanding until that day, plus new fails that occur that day, less fails that settle that day. The figure is not a daily amount of fails, but a combined figure that includes both new fails on the reporting day as well as existing fails. In other words, these numbers reflect aggregate fails as of a specific point in time, and may have little or no relationship to yesterday’s aggregate fails.

Genocea Biosciences Inc. shares plummeted late Monday after the tiny Cambridge, Mass.-based biotech said it was shifting its drug development focus and cutting staff by 40%. Investor HG Vora sees the real glitter in the company’s parts, and could have plans to boost shareholder value. Also, filings on Prevail Therapeutics, Universal Stainless & Alloy, Seres Therapeutics, Tivity Health, Chaparr…

We have 9 different ratings for every stock to help you appreciate its future potential. Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing. Moreover, the increasing expense and loss also raised doubts about the company continuing as a going concern. In the first quarter of 2022, the loss from operations was $15.8 million while it used $15.2 million of cash in operating activities.

Nasdaq

Unable to find any means to save the company, GNCA said on Tuesday that it has decided to completely wind down its operations. The company is even letting go of the remaining staff, just leaving the essential few for completing the wind-down process. You may use StockInvest.us and the contents contained in StockInvest.us solely for your own individual non-commercial and informational purposes only. Any other use, including for any commercial purposes, is strictly prohibited without our express prior written consent. Featured in The Global Fintech Index 2020 as the top Fintech company of the country.

It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Similarly, a stock that is in a downtrend must be out of favor.InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

MarketWatch

Heading into the fourth quarter of 2020, a total of 10 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 0% from the previous quarter. Below, you can check out the change in hedge fund sentiment towards GNCA over the last 21 quarters. So, let’s check out which hedge funds were among the top holders of the stock and which hedge funds were making big moves. The combined on-exchange and off-exchange short sale volume for GNCA / Genocea Biosciences Inc is provided in the table below. In order to calculate an accurate short volume ratio, we gather data from a number of trading venues, but not ALL trading venues.

These returns cover a period from January 1, 1988 through April 3, 2023. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Private Companies

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. It is a small sample, and it is useful for tracking the rise and fall in demand for shares throughout the day and weeks. It should not be treated as an absolute number of shares that are available to short in the market. GNCA tried its best to deliver a working drug and start generating revenue.

For more information on how to interpret this data, read this information notice provided by FINRA. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. It seems investors are making a run for some final profits from the stock before the company closes down for good and delists from the exchange. This is the only plausible explanation for the after-hours rebound of the stock as there is nothing left in the company to be buying the stock.

• But the good news is, if China invades Taiwan, there is a way to protect yourself.
• Short Interest is the total number of open short positions of a security.
• Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
• Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
• That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
• We believe the stock, after the recent drop, may trend higher in the near term.

Plus, you can see the Zacks #1 Rank Stocks with a VGM of A or B. You can also sort the list with criteria you choose, view Additions and Deletions by day, and Performance. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Here’s The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings. A preclinical poster presented at the meeting demonstrates how detrimental these Inhibigens are to the efficacy of cancer therapeutics in mouse models of melanoma and pancreatic cancer. Additional data presented at AACR highlights ongoing work characterizing inhibitory antigens or Inhibigens.

Companies with women executives can help you do better in the stock market

The brics 2019 summit declaration free trade agreement was founded in 2006 and is based in Cambridge, Massachusetts. Yesterday, the company delivered a formal notice to The Nasdaq Stock Market Inc. regarding its voluntary delisting from the exchange. The company plans to file a Form 25 with the SEC by June 2 in order to effect the voluntary delisting while it already was facing the threat.

It even onboarded professional advisors and an investment bank to help it find a solution to its woes. Options on the table included the partial or complete sale of the company and a merger or reverse merger. In an effort to raise funds, the company had also an agreement with Cowen for an at-the-market equity offering.

However, with no meaningful results from any of its trial progress and a dwindling cash position, the company commenced restructuring last month. It even laid off 65% of its staff and was evaluating its R&D programs. The biotech firm was exploring its strategic alternatives to improve shareholder value and save it from its downfall. But the latest news of a complete wind-down and delisting from Nasdaq concluded that the company failed to achieve any results from the review process.

But the good news is, if China invades Taiwan, there is a way to protect yourself. We update our database every 30 minutes but only display changes, in order to improve readability. You can see the full Zacks #1 Rank List or narrow it down to Zacks #1 Rank Stocks with a Value, Growth, Momentum or Income Style Score of A or B.

Get Free Updates

2 Wall Street research analysts have issued «buy,» «hold,» and «sell» ratings for Genocea Biosciences in the last twelve months. The consensus among Wall Street research analysts is that investors should «hold» GNCA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GNCA, but not buy additional shares or sell existing shares.

The https://1investing.in/ Interestfigures we provide are sourced directly from the stock exchanges and FINRA. We get this data directly from those agencies on a daily or twice-weekly basis. The float and shares outstandingwe use are sourced from Capital IQ, which is one of the top firms that provide this data. Today’s news has GNCA stock seeing heavy trading with some 81 million shares on the move as of this writing. For comparison, the company’s daily average trading volume is closer to 3.5 million shares.

• Genocea Biosciences Inc stock is unchanged 0.00% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.
• Analysts like Genocea Biosciences less than other Medical companies.
• As per the Q1 report, the company expected its cash balance to lead it to just the next quarter, Q3 2022.
• The biotechnology company had devoted most of its efforts to product research and development but had not generated any product revenue to date.

When it is time to report, any open short positions are reported, no matter what type of trading venue those shares were acquired on. This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by frequency of updates, with intraday data at the top , daily data (short volume, fails-to-deliver) in the middle, and the slowest updated data at the bottom. Note that short interest is published twice-monthly, on a schedule a set by FINRA. The chart below shows how a company’s ratings by analysts have changed over time.

View All

In a report released today, Gil Blum from Needham maintained a Buy rating on Genocea Biosciences (GNCA – Research Report), with a price target of $6.00. The company’s shares closed last Tuesday at $1.13, close to its 52-week low of $0.92. According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.0% and a 16.4% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. Genocea Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $7.25, a 470.9% upside from current levels. In investing, sentiment generally means whether or not a given security is in favor with investors.

Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. Click Here to get the full Stock Report for Genocea Biosciences Inc stock. StockInvest.us is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data. The last nail in GNCA’s coffin was its non-compliance with Nasdaq listing standards due to its share price. The company’s shares have been closing below the required $1.0 per share for more than consecutive 30 days. This led to the exchange notifying the company as it was facing a threat of delisting its shares.